Migraine – Landscape & Forecast – Disease Landscape & Forecast (G7)

Migraine, which afflicts approximately 73 million people in the major pharmaceutical markets according to Clarivate Epidemiology, is a heterogeneous condition requiring individualized treatment mainly based on a patient’s symptoms and needs, headache pattern, comorbidities, contraindications, and treatment history. With the launch of calcitonin gene-related peptide (CGRP)-targeted, migraine-specific treatment alternatives to standard-of-care (SOC) therapies (e.g., anti-CGRP MAbs for migraine prevention, oral CGRP receptor antagonists for both the treatment of acute migraine attacks and migraine prevention) and the expected launches of several reformulations of SOC therapies in the near term in the United States, brand choice has rapidly expanded in this heavily generic market. Understanding the intersecting forces of unmet need, cost/coverage, and the headwinds posed by low-cost, early-line SOC treatments will be key to the success of current and future players in the migraine market.

Questions answered

• What events will shape the future of the acute/preventive and episodic/chronic market segments? What patient share will Lundbeck’s anti-PACAP38 MAb, LU-AG09222, garner by the end of our forecast period?
• How are the anti-CGRP MAbs (e.g., Aimovig) and oral gepants (e.g., Nurtec ODT/Vydura, Qulipta) being integrated into the generic-dominant migraine prophylaxis market? Which brands will be the most competitive and why?

• What is the dynamic between Ubrelvy and Nurtec ODT in the U.S. market? How are oral gepants being adopted into the triptan-dominant acute segment?

• How will novel reformulations compete for patient share with existing options in the niche segment of patients who need non-oral alternatives?

Geography: United States, EU5, Japan

Primary research: Country-specific interviews with thought-leading neurologists; survey data collected for this and other Clarivate research

Epidemiology: Total, diagnosed, and drug-treated prevalent cases of episodic and chronic migraine, segmented by acute and prophylactic treatment.

Drug treatments: Coverage of key current and late-phase emerging therapies

Forecast: 10-year, annualized, drug-level sales and patient share of key acute and prophylactic migraine therapies through 2034, segmented by brands/generics and epidemiological subpopulations

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy. 
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.